Redeye expects Smart Eye’s Q1 report, due May 13, to show 12% y/y net sales growth and an EBITDA imp...
Redeye shares its preview of BONESUPPORT’s Q1 2025 results, due April 24.
Redeye returns with an updated take on NextCell following the inconclusive interim analysis, which h...
Genetic Analysis AS (”Genetic Analysis” or ”the Company”) has developed the GA-map®, a platform for ...
Redeye provides a short comment on the trading update from Cheffelo released earlier this morning.
Redeye sees the acquisition of Welotec as a strategically sound move with relatively low risks.
XVIVO is likely to enter 2025 with a modest quarter during a period of macro-economic worries.
Redeye gives its view on mezagitamab, whose phase III start triggered a milestone payment to BioInve...
Redeye sees an interesting opportunity in Transtema, which is trading close to its four-year low des...
We believe organic growth could be negative y/y for Q1 2025.
Redeye comments on the acquisition announced this morning, where Dynavox Group acquires its long-tim...
Redeye comments on the preliminary one-year results from the ProTrans-Young trial, announced by Next...
Relais announced today that it will acquire a majority stake in Matro Group, a well-established dist...
Umida Group AB (”Umida”, ”Koncernen” eller ”Bolaget”) meddelade den 7 april år 2025 att Bolaget har ...
Medtech is not exempt from US reciprocal tariffs, unlike Pharma.
Mangold återupptar bevakning av investmentbolaget Archelon Natural Resources "Archelon".
On April 4th, STENOCARE announced that the innovative ASTRUM 10-10 has obtained for approval for rei...
Incorporating Doro lifts '26e-'27e EBITA by 25-53% We forecast a '25e-'28e EBITA CAGR of 32%.
Redeye provides a research note on Faron Pharmaceuticals following the announcement of a convertible...